- Absci plans a Phase 2 double-blind, randomized, placebo-controlled trial of ABS-201 for endometriosis.
Absci Corp released plans for a Phase 2 clinical trial evaluating ABS-201, an anti-prolactin receptor antibody, in endometriosis. The STORYLINE trial targets 150 patients across 10+ countries with a mid-2027 start, pending regulatory clearance.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.